KRAS and lung carcinoma: Altogether, these results demonstrate that HOXC10 inhibition and TTI-101 combination has dramatic effects on key ferroptosis mediators in KRAS-mutant lung cancer bone metastasis cells, including cellular ROS and GSH levels.